Nebido — How Long Does It Last and What Does the Therapy Look Like?

Understand

Overview

Nebido is the brand name for testosterone undecanoate — testosterone esterified with undecanoic acid, an eleven-carbon fatty acid, which makes it by far the most lipophilic and longest-acting testosterone ester used in routine clinical practice. That's a fundamental pharmacological difference from the far more common esters covered elsewhere on this site — enanthate and cypionate — which require injections every one to two weeks. After an initial loading phase, Nebido is typically given once every 10 to 14 weeks, meaning four to five injections a year instead of dozens. That's a radically different treatment rhythm, and for some patients it's the main reason to choose this product — but it also comes with a different course of treatment, a different blood concentration curve, and a requirement that the drug be administered only in a medical setting.

An actual course of Nebido therapy starts with a loading phase. Based on the description of the standard regimen for this product (1000mg in 4mL of castor oil) in the paper by Morales and colleagues, the first injection is given at week zero, the second already at week six — noticeably sooner than the eventual maintenance rhythm would suggest — and only from that point does the regimen move into a maintenance phase with injections every twelve weeks, individually fine-tuned within a window of ten to fourteen weeks depending on the testosterone concentration measured just before the next injection (the so-called trough level). That earlier second dose has one purpose: to build up a sufficient depot of drug in the muscle tissue before the intervals between injections stretch out, so that testosterone levels don't drop below the therapeutic range before the depot from the first dose is topped up.

Nebido's pharmacokinetic curve is noticeably flatter than that of the shorter esters, which produce a clear concentration peak in the first few days after injection followed by a gradual decline until the next dose. In an 84-week phase III trial by Wang and colleagues involving 130 hypogonadal men (baseline testosterone below 300 ng/dL), the trough testosterone concentration — measured right before the next dose — stayed within the normal adult male range of 300–1000 ng/dL (10.4–34.7 nmol/L) from the very first injection onward, and DHT, estradiol, and their ratios to testosterone remained stable once steady state was reached. It's worth flagging one important, potentially confusing detail here: this trial used a 750mg dose in 3mL — the formulation registered in the US under the name Aveed — rather than the 1000mg in 4mL that is the European standard described by Morales. So if a reader comes across the name Aveed elsewhere, it's worth knowing that it's the same active substance (testosterone undecanoate) at a different dose and volume, registered under a different regulatory system — not a different drug.

In practice, this means that starting Nebido therapy looks different from starting a short-ester regimen. Every injection is 4mL of an oily solution given as a deep intramuscular injection, usually into the gluteal muscle — a considerably larger volume than a typical enanthate or cypionate dose, which in itself calls for more technical precision when administering it. The drug isn't meant for self-administration at home: every injection takes place at a doctor's office or clinic, and the less frequent visit schedule (once every several weeks instead of weekly) is, for some patients, a meaningful organizational advantage, even though a single visit takes longer than a routine injection because of the required post-injection observation period.

That observation requirement isn't a formality — it stems from a real, documented safety signal specific to oily, high-volume testosterone undecanoate preparations: pulmonary oil microembolism (POME) and, less often, anaphylactic reactions related to the oily vehicle's components. A review by Adam and colleagues, covering 48 publications including 29 studies and nearly 8,000 patients treated with testosterone undecanoate, identified a combined 88 episodes of POME or post-injection cough across eight of those studies, and one postmarketing review recorded 223 cases out of 3,107,652 injections given — a fraction of a percent, but not zero, and serious enough that the FDA in the United States mandated a REMS (Risk Evaluation and Mitigation Strategy) program for the Aveed product, requiring at least 30 minutes of in-office patient observation after every dose. A postmarketing analysis by Pastuszak and colleagues, covering 4.3 years of surveillance (March 2014 to June 2018), reviewed 90,092 doses distributed and 633 safety reports, of which 28 confirmed POME cases were identified — a yearly reporting rate under 0.1% per injection. The large majority of episodes resolved on their own: of the cases described in detail, 13 of 17 resolved within 30 minutes or less, and over 60% required no medical intervention at all. One death was reported 18 months after a POME event but, on review, was judged unrelated to it, while in three of the four cases that required emergency-room-level care, errors in injection technique or dosing were implicated — a useful practical reminder that correct technique meaningfully reduces the risk.

Long-term data confirm that, when properly managed, Nebido therapy normalizes testosterone levels effectively and durably. The nine-year TRACK_9 registry followed 650 patients across 4,362 treatment-years on 1000mg testosterone undecanoate — that is, exactly the Nebido regimen — showing a rise in testosterone from 6.6±2.4 to 19.3±2.9 nmol/L (p<0.001), while also recording, over long-term follow-up, low but nonzero rates of hematocrit rising above 50% and PSA increases within the cohort — parameters that require regular monitoring in any TRT regimen, regardless of the ester chosen. Nebido tends to suit patients who value a much less frequent injection schedule and a flat concentration curve, provided they accept that every dose requires a visit to a medical facility with post-injection observation — never a self-administered injection at home. Decisions about dose, the length of intervals between injections, and any adjustment to the regimen belong solely to the prescribing physician, based on regularly monitored bloodwork.

History of use

Oral testosterone undecanoate (under names such as Andriol or Restandol) has been used clinically since the 1970s, exploiting absorption via the intestinal lymphatic vessels to bypass extensive first-pass liver metabolism. The long-acting intramuscular form was developed and clinically tested much later — the key pharmacokinetic and safety studies, including those describing the standard 1000mg dosing schedule given every 10–14 weeks after a loading phase, date to the mid-2000s. The product was registered in the European Union under the name Nebido, and only later in the United States, under the name Aveed, at a different dose (750mg in 3mL) and with an additional FDA-mandated REMS program requiring patient observation after every injection — a regulatory response to accumulated data on the risk of pulmonary oil microembolism and anaphylaxis.